Estramustine

Sarcoma

NYU Langone HealthSmall moleculePhase 1/2Dormant

CC

46/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 37/ 100
Competitive Position: 73/ 100

Competitive context

110 Active assets in the Sarcoma cohort.

Asset / Sponsor	Phase	Rating
ETOPOSIDE National Cancer Institute (NCI)	Phase 2	BB
Cyclophosphamide Essen Biotech	Phase 2	BB
Ifosfamide City of Hope Medical Center	Phase 3	BB
Inno-206 City of Hope Medical Center	Phase 3	BB
Carboplatin OHSU Knight Cancer Institute	Phase 2	BB

View all 50 →

Same molecule, other indications

Estramustine is also rated in:

prostate cancerDormant

BB

Indicative ·

70 / 100

prostate adenocarcinomaDormant

B

Indicative ·

63 / 100

prostate neoplasmDormant

B

Indicative ·

59 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.